149 related articles for article (PubMed ID: 26462118)
1. Hypomethylating agents are effective in shrinking splenomegaly in patients with chronic myelomonocytic leukemia.
Subari S; Patnaik M; Alfakara D; Zblewski D; Hook C; Hashmi S; Hogan W; Litzow M; Al-Kali A
Leuk Lymphoma; 2016 Jul; 57(7):1714-5. PubMed ID: 26462118
[No Abstract] [Full Text] [Related]
2. Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents.
Duchmann M; Braun T; Micol JB; Platzbecker U; Park S; Pilorge S; Beyne-Rauzy O; Vey N; Sébert M; Gruson B; Dumas PY; Guieze R; Chretien ML; Laribi K; Chait Y; Legros L; Sahnes L; Hirsch P; Salanoubat C; Solary E; Fenaux P; Itzykson R
Blood Cancer J; 2017 May; 7(5):e562. PubMed ID: 28498370
[No Abstract] [Full Text] [Related]
3. Acquired alpha thalassemia myelodyslastic/myeloproliferative syndrome (ATMDS): evolution on hypomethylating agent therapy.
Rose C; Fournier M; Nibourel O; Herbaux C; Charpentier A; Renneville A; Pissard S; Badens C; Preudhomme C
Leuk Res; 2011 Nov; 35(11):e203-5. PubMed ID: 21831427
[No Abstract] [Full Text] [Related]
4. A rare case of acquired haemophilia in a patient with chronic myelomonocytic leukaemia successfully treated with decitabine.
Shah D; Kumar R; Gaikazian S
Haemophilia; 2014 Jan; 20(1):e92-4. PubMed ID: 24261579
[No Abstract] [Full Text] [Related]
5. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
Aribi A; Borthakur G; Ravandi F; Shan J; Davisson J; Cortes J; Kantarjian H
Cancer; 2007 Feb; 109(4):713-7. PubMed ID: 17219444
[TBL] [Abstract][Full Text] [Related]
6. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
7. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.
Zeidan AM; Hu X; Long JB; Wang R; Ma X; Podoltsev NA; Huntington SF; Gore SD; Davidoff AJ
Cancer; 2017 Oct; 123(19):3754-3762. PubMed ID: 28621841
[TBL] [Abstract][Full Text] [Related]
8. Monocytic skin nodules in chronic myelomonocytic leukemia: clinical response to decitabine therapy.
Steensma DP; Friday BB
Leuk Lymphoma; 2007 Aug; 48(8):1628-9. PubMed ID: 17701595
[No Abstract] [Full Text] [Related]
9. [Treatment of two chronic myelomonocytic leukemia patients with Decitabine].
Wang L; Wang HX; Zhao J
Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):497. PubMed ID: 22213878
[No Abstract] [Full Text] [Related]
10. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
11. Chronic myelomonocytic leukemia coexisting with monoclonal gammopathy: concomitant response to azacitidine of both disorders.
Niscola P; Siniscalchi A; Tendas A; Scaramucci L; Fratoni S; de Fabritiis P; Caravita T
Ann Hematol; 2015 Oct; 94(10):1753-4. PubMed ID: 26088814
[No Abstract] [Full Text] [Related]
12. The role of hypomethylating agents in the treatment of elderly patients with AML.
Al-Ali HK; Jaekel N; Niederwieser D
J Geriatr Oncol; 2014 Jan; 5(1):89-105. PubMed ID: 24484723
[TBL] [Abstract][Full Text] [Related]
13. Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.
Oki Y; Jelinek J; Shen L; Kantarjian HM; Issa JP
Blood; 2008 Feb; 111(4):2382-4. PubMed ID: 18055864
[TBL] [Abstract][Full Text] [Related]
14. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.
Merlevede J; Droin N; Qin T; Meldi K; Yoshida K; Morabito M; Chautard E; Auboeuf D; Fenaux P; Braun T; Itzykson R; de Botton S; Quesnel B; Commes T; Jourdan E; Vainchenker W; Bernard O; Pata-Merci N; Solier S; Gayevskiy V; Dinger ME; Cowley MJ; Selimoglu-Buet D; Meyer V; Artiguenave F; Deleuze JF; Preudhomme C; Stratton MR; Alexandrov LB; Padron E; Ogawa S; Koscielny S; Figueroa M; Solary E
Nat Commun; 2016 Feb; 7():10767. PubMed ID: 26908133
[TBL] [Abstract][Full Text] [Related]
15. Hypomethylating agents in the treatment of chronic myelomonocytic leukemia: a meta-analysis and systematic review.
Xu R; Li M; Wu P; Deng C; Geng S; Huang X; Weng J; Du X
Hematology; 2021 Dec; 26(1):312-320. PubMed ID: 33706667
[TBL] [Abstract][Full Text] [Related]
16. Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia.
Berg JL; Perfler B; Hatzl S; Mayer MC; Wurm S; Uhl B; Reinisch A; Klymiuk I; Tierling S; Pregartner G; Bachmaier G; Berghold A; Geissler K; Pichler M; Hoefler G; Strobl H; Wölfler A; Sill H; Zebisch A
Clin Epigenetics; 2021 Jan; 13(1):1. PubMed ID: 33407852
[TBL] [Abstract][Full Text] [Related]
17. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia.
Meldi K; Qin T; Buchi F; Droin N; Sotzen J; Micol JB; Selimoglu-Buet D; Masala E; Allione B; Gioia D; Poloni A; Lunghi M; Solary E; Abdel-Wahab O; Santini V; Figueroa ME
J Clin Invest; 2015 May; 125(5):1857-72. PubMed ID: 25822018
[TBL] [Abstract][Full Text] [Related]
18. Activity of azacitidine in chronic myelomonocytic leukemia.
Costa R; Abdulhaq H; Haq B; Shadduck RK; Latsko J; Zenati M; Atem FD; Rossetti JM; Sahovic EA; Lister J
Cancer; 2011 Jun; 117(12):2690-6. PubMed ID: 21656746
[TBL] [Abstract][Full Text] [Related]
19. Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
Alfonso A; Montalban-Bravo G; Takahashi K; Jabbour EJ; Kadia T; Ravandi F; Cortes J; Estrov Z; Borthakur G; Pemmaraju N; Konopleva M; Bueso-Ramos C; Pierce S; Kantarjian H; Garcia-Manero G
Am J Hematol; 2017 Jul; 92(7):599-606. PubMed ID: 28370097
[TBL] [Abstract][Full Text] [Related]
20. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
